Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Affinity Asset Advisors, LLC
Form 13F · Q2 2026

Affinity Asset Advisors, LLC

CIK 1773195Filed 2026-08-1313F-HR View the filing on EDGAR ↗
$2.2B
Reported book value
113
Positions
12
Quarters on record
Top 50
Positions

Affinity Asset Advisors, LLC — holdings

Top 50 positions of 113, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1ROIV Roivant Sciences Ltd3.8M+33.9%$133M6.0%
2APOGEE THERAPEUTICS INC Apogee Therapeutics Inc987,000−23.2%$131M5.9%
3SYRE Spyre Therapeutics Inc1.3M+0.0%$114M5.1%
4XENE Xenon Pharmaceuticals Inc1.6M−4.8%$96M4.4%
5ERAS Erasca Inc5.2M−1.9%$96M4.3%
6INSM Insmed Inc650,000+35.4%$69M3.1%
7PRAX Praxis Precision Medicines I185,000+8.8%$62M2.8%
8ALKS Alkermes Plc1.1M−16.7%$59M2.7%
9ORKA Oruka Therapeutics Inc590,000+18.1%$56M2.5%
10ANAB Anaptysbio Inc826,109−12.1%$56M2.5%
11AVTX Avalo Therapeutics Inc2.9M+116.3%$54M2.4%
12CYTK Cytokinetics Inc550,000−21.5%$47M2.1%
13RVMD Revolution Medicines Inc250,000+150.0%$47M2.1%
14ABIVAX SA Abivax Sa330,000−18.5%$44M2.0%
15TRAX First Tracks Biotherapeutics2.0M—$41M1.8%
16DNTH Dianthus Therapeutics Inc400,000+14.3%$39M1.8%
17STRO Sutro Biopharma Inc1.2M+9.6%$39M1.8%
18NUVALENT INC Nuvalent Inc275,000−8.3%$34M1.5%
19TRVI Trevi Therapeutics Inc1.8M−10.0%$34M1.5%
20OVID Ovid Therapeutics Inc10.1M−4.6%$27M1.2%
21LXEO Lexeo Therapeutics Inc5.8M+15.0%$27M1.2%
22CLDX Celldex Therapeutics Inc New700,000+40.0%$26M1.2%
23BLTE Belite Bio Inc165,000+153.8%$25M1.1%
24ELVN Enliven Therapeutics Inc500,000−14.8%$25M1.1%
25FORTE BIOSCIENCES INC Forte Biosciences Inc1.1M+13.2%$24M1.1%
26NRIX Nurix Therapeutics Inc967,620+0.0%$23M1.1%
27ANRO Alto Neuroscience Inc850,000+70.0%$22M1.0%
28MDGL Madrigal Pharmaceuticals Inc40,000−27.3%$21M1.0%
29PTGX Protagonist Therapeutics Inc172,125+0.0%$21M1.0%
30MLYS Mineralys Therapeutics Inc750,000+0.0%$20M0.9%
31RLAY Relay Therapeutics Inc1.1M+162.5%$20M0.9%
32SGMT Sagimet Biosciences Inc2.5M+187.8%$19M0.9%
33JBIO Jade Biosciences Inc840,350+31.3%$19M0.8%
34COGT Cogent Biosciences Inc450,000−40.0%$17M0.8%
35TVTX Travere Therapeutics Inc300,000+0.0%$17M0.8%
36CGEM Cullinan Therapeutics Inc875,760+12.1%$16M0.7%
37SVRA Savara Inc2.5M+0.0%$15M0.7%
38IDYA Ideaya Biosciences Inc400,000—$15M0.7%
39CATX Perspective Therapeutics Inc4.2M+33.2%$14M0.6%
40ODTX Odyssey Therapeutics Inc766,346—$14M0.6%
41HLXC Helix Acquisition Corp Iii1.2M+0.0%$13M0.6%
42EQ Equillium Inc4.1M+234.3%$13M0.6%
43ESTA Establishment Labs Hldgs Inc148,013+48.0%$13M0.6%
44CLYM Climb Bio Inc972,000+38.9%$13M0.6%
45TEVA PHARMACEUTICAL INDS LTD Teva Pharmaceutical Inds Ltd374,000−73.3%$13M0.6%
46MANE Veradermics Inc100,000+42.9%$12M0.6%
47ARWR Arrowhead Pharmaceuticals In150,000−25.0%$12M0.6%
48TSHA Taysha Gene Therapies Inc1.8M+75.0%$12M0.5%
49DMRA Damora Therapeutics Inc425,000−5.6%$11M0.5%
50EPRX Eupraxia Pharmaceuticals Inc1.6M+3.8%$11M0.5%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.